Let-7f-5p and application of target gene thereof for preparing medicine for treating osteoporosis

A technology of let-7f-5p, 1.let-7f-5p, applied in the application field of drugs for the treatment of osteoporosis, to achieve the effect of reducing bone loss

Inactive Publication Date: 2019-10-01
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently providing effective OP treatment remains a challenge
The recommended drugs for the treatment of OP, such as bisphosphonates and teriparatide, have relatively serious side effects, such as nausea, upper abdominal pain, indigestion, gastritis, back pain, and joint pain; and teriparatide needs to be injected every day , can receive only one 24-month treatment in lifetime

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Let-7f-5p and application of target gene thereof for preparing medicine for treating osteoporosis
  • Let-7f-5p and application of target gene thereof for preparing medicine for treating osteoporosis
  • Let-7f-5p and application of target gene thereof for preparing medicine for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] High-throughput sequencing screening.

[0042] 1. High-throughput sequencing

[0043] 1.1 Method.

[0044] Using high-throughput sequencing, we screened the differential miRNAs of vertebral body tissues in the GIOP patient group and the control group (non-GIOP patients) from the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, and predicted and verified their target genes. At the same time, predict differential miRNAs target genes in MiRanda, MiRBase and TargetScan databases.

[0045] 1.2 Results.

[0046] The result is figure 1 As shown, figure 1 It is the cluster analysis diagram of miRNA between the GIOP patient group and the control group, where: GIOP is the GIOP patient group, and CON is the control group. It was found that miRNA let-7f-5p was differentially expressed.

[0047] 2. qRT-PCR verification

[0048] 1.1 Method.

[0049] The qRT-PCR method was used to verify and compare the expression of miRNA let-7f-5p between the GIOP patient grou...

Embodiment 2

[0054] The animal experiment verification of miRNA let-7f-5p as a medicine for treating osteoporosis.

[0055] 1. Let-7f-5p promotes osteogenic differentiation.

[0056] 1 method.

[0057] The long bones (tibia and femur) of 8-week-old mice were aseptically removed, and the bone marrow was washed with α-MEM containing 20% ​​fetal bovine serum. Filtered with a 40μm cell strainer to obtain mouse bone marrow derived-mesenchymal stem cells (BMSCs), which were placed in a 35mm culture dish at 4×10 4 / cm 2 The density is at 37℃, 5% CO 2 Cultivate for 4 days.

[0058] The above-mentioned cultured BMSCs cells were seeded into a 12-well plate, and osteogenic induction medium (in a-MEM containing 25mg / mL L-ascorbic acid, 5mM β-glycerophosphate, 10% FBS) was used to induce osteogenic differentiation, and let -7f-5p mimics (single-stranded chemically enhanced oligonucleotides, let-7f-5p mimics, purchased from Guangzhou Ruibo Biotechnology Co., Ltd.) intervention, that is, let-7f-5p mimics (to ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of a target mRNA of let-7f-5p for preparing medicine for treating osteoporosis, and belongs to the technical field of biologic medicine. Experiments verify that let-7f-5p mimics can reverse reduction of osteogenesis differentiation under GC induction; in-vivo experiments also verify that let-7f-5p tail intravenous injection can reduce loss of the GIOP mouse bone mass. Meanwhile, the let-7f-5p and a TGFBR1 gene have the target relationship, the let-7f-5p and the target gene thereof can be applied as a target for treating osteoporosis, a novel target is supplied by treatment adopting miRNA let-7f-5p and a target gene thereof as OP, and a novel therapeutic drug is supplied by treatment adopting miRNA let-7f-5p as OP.

Description

Technical field [0001] The present invention relates to the field of biomedical technology, in particular to the application of let-7f-5p and its target gene in the preparation of a medicine for treating osteoporosis. Background technique [0002] Osteoporosis (Osteoporosis, OP) is a metabolic disease in which bone mass per unit volume is reduced, the microstructure of bone tissue changes, and bone fragility increases, so that fractures are prone to occur. As human beings enter an aging society, the incidence of OP in countries around the world is increasing year by year, and it is prone to severe complications such as fractures, which seriously threatens human health, and also causes a heavy economic burden on society and families. [0003] To study the pathogenesis of OP and find the prevention and treatment targets of OP has become an urgent clinical need. However, currently providing effective OP treatment remains a challenge. The recommended drugs for the treatment of OP, su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7105A61P19/10C12Q1/6883
CPCA61K31/7105A61P19/10C12Q1/6883C12Q2600/106C12Q2600/178
Inventor 江晓兵沈耿杨任辉尚奇梁德招文华张志达余翔黄锦菁何嘉辉梁梓扬唐晶晶
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap